L-M Tseng

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

Javier Cortés, S-B. Kim, W-P. Chung et al. · Annals of Oncology · 2021 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract S6-01: <i>PIK3CA</i> status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial

J. Baselga, S-A. Im, Hiroji Iwata et al. · Cancer Research · 2016 · 88 citations

Medicine, Oncology, Pharmacology +17

Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')

Luca Gianni, Tadeusz Pieńkowski, Y-H Im et al. · Cancer Research · 2010 · 67 citations

Medicine, Oncology, Pharmacology +17

377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

S.A. Hurvitz, Shanu Modi, Wěi Li et al. · Annals of Oncology · 2023 · 58 citations · Full text

Medicine, Oncology, Breast Oncology +15

S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC).

Luca Gianni, Giampaolo Bianchini, Astrid Kiermaier et al. · Cancer Research · 2011 · 49 citations

Medicine, Molecular Medicine, Oncology +17